| Filed On | Filing |
|---|---|
| 17 Apr 2024 |
8-K/A: Financial Statements and Exhibits
We have audited the consolidated financial statements of C2I Genomics Inc. (the "Company"), which comprise the consolidated balance sheet as of December 31, 2023, and the related consolidated statements of operations, changes in converti... |
| 08 Jun 2021 |
8-K/A: Entry into a Material Definitive Agreement
Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities |
| 18 Feb 2020 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined balance sheet is presented to give effect to the agreement with NanoString Technologies, Inc., or NanoString, for (i) the acquisition of certain assets and liabilities related to the n... |
| 13 Jun 2019 |
8-K/A: Submission of Matters to a Vote of Security Holders
(d) As previously reported by the Company, at the Company’s 2019 Annual Meeting of Stockholders held on June 11, 2019, the Company’s stockholders selected, on a non-binding advisory basis, one year as the frequency with which the Company... |
| 21 May 2015 |
8-K/A: Financial Statements and Exhibits
On September 16, 2014, Allegro Diagnostics Corp. (“Allegro”) merged with Full Moon Acquisition, Inc., a wholly-owned subsidiary of Veracyte, Inc. (“Veracyte” or the “Company”), (“Merger”) with Allegro surviving the Merger as a wholly-own... |
| 10 Dec 2014 |
8-K/A: Financial Statements and Exhibits
On September 16, 2014, Allegro Diagnostics Corp. (“Allegro”) merged with Full Moon Acquisition, Inc., a wholly-owned subsidiary of Veracyte, Inc. (“Veracyte” or the “Company”), (“Merger”) with Allegro surviving the Merger as a wholly-own... |
| 06 Nov 2014 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying financial statements of Allegro Diagnostics Corp., which comprise the balance sheet as of December 31, 2013, and the related statements of operations, of changes in redeemable convertible preferred stock ... |
Loading...